Verici Dx Plc (VRCI) - Total Assets
Based on the latest financial reports, Verici Dx Plc (VRCI) holds total assets worth GBX4.54 Million GBX (≈ $553.00 USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Verici Dx Plc (VRCI) net asset quality to measure how much of total assets are equity-financed.
Verici Dx Plc - Total Assets Trend (2020–2024)
This chart illustrates how Verici Dx Plc's total assets have evolved over time, based on quarterly financial data. Check VRCI tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Verici Dx Plc - Asset Composition Analysis
Current Asset Composition (December 2024)
Verici Dx Plc's total assets of GBX4.54 Million consist of 60.9% current assets and 39.1% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 54.2% |
| Accounts Receivable | GBX0.00 | 0.0% |
| Inventory | GBX0.00 | 0.0% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX2.07 Million | 27.6% |
| Goodwill | GBX0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Verici Dx Plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Verici Dx Plc market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Verici Dx Plc's current assets represent 60.9% of total assets in 2024, a decrease from 89.0% in 2020.
- Cash Position: Cash and equivalents constituted 54.2% of total assets in 2024, down from 87.4% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 27.0% of total assets, an increase from 8.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 27.6% of total assets.
Verici Dx Plc Competitors by Total Assets
Key competitors of Verici Dx Plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fleury S.A.
SA:FLRY3
|
Brazil | R$13.33 Billion |
|
Wuhan Thalys Med Tech Co Ltd
SHG:603716
|
China | CN¥1.74 Billion |
|
Spectral Med Inc
TO:EDT
|
Canada | CA$8.12 Million |
|
Bcal Diagnostics Ltd
AU:BDX
|
Australia | AU$7.17 Million |
|
Genetic Signatures Ltd
AU:GSS
|
Australia | AU$49.04 Million |
|
ALPHAHELIX MOL.DIAGN. SK1
F:4MB
|
Germany | €13.12 Million |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
Verici Dx Plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.91 | 4.54 | 9.39 |
| Quick Ratio | 0.91 | 4.34 | 9.39 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX-174.00K | GBX6.98 Million | GBX15.72 Million |
Verici Dx Plc - Advanced Valuation Insights
This section examines the relationship between Verici Dx Plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.93 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 0.7% |
| Total Assets | GBX7.49 Million |
| Market Capitalization | $69.05K USD |
Valuation Analysis
Below Book Valuation: The market values Verici Dx Plc's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Verici Dx Plc's assets grew by 0.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Verici Dx Plc (2020–2024)
The table below shows the annual total assets of Verici Dx Plc from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | GBX7.49 Million ≈ $911.56 |
+0.66% |
| 2023-12-31 | GBX7.44 Million ≈ $905.60 |
-47.97% |
| 2022-12-31 | GBX14.30 Million ≈ $1.74K |
+3.74% |
| 2021-12-31 | GBX13.79 Million ≈ $1.68K |
-32.09% |
| 2020-12-31 | GBX20.31 Million ≈ $2.47K |
-- |
About Verici Dx Plc
Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failur… Read more